The Price of a Baby: How America's Unregulated Fertility Industry Turned Parenthood Into a Luxury Good

The $20,000 Question Nobody in Washington Is Asking

In the spring of 2025, the American Society for Reproductive Medicine estimated that fewer than one-third of U.S. employers offer meaningful fertility benefits, and the average cost of a single in vitro fertilization cycle — without any guarantee of success — now runs between $15,000 and $25,000 when medications, monitoring, and lab fees are fully accounted for. Many patients require two, three, or more cycles before achieving a live birth. Do the math, and you arrive at a figure that places parenthood, for millions of working and middle-class Americans, somewhere between a second mortgage and a financial catastrophe.

This is not a niche issue. According to the Centers for Disease Control and Prevention, roughly one in five married women in the United States between the ages of 15 and 49 experience difficulty getting pregnant or carrying a pregnancy to term. Infertility is a medical condition — recognized as such by the World Health Organization — and yet the United States remains one of the only wealthy democracies where treatment for that condition is overwhelmingly left to the private market, unregulated at the federal level, and inaccessible to anyone without either a generous employer or a sizable savings account.

A Market Built on Desperation

The fertility industry in America is a $9 billion enterprise, and it is growing. Venture capital and private equity firms have spent the last decade snapping up independent clinics and consolidating them into regional and national chains. Companies like CCRM, Shady Grove Fertility, and US Fertility — the latter backed by Amulet Capital Partners — now operate dozens of locations across multiple states, standardizing protocols and, critics argue, prioritizing throughput over individualized care.

What does consolidation mean for patients? It tends to mean higher prices, fewer negotiations, and a customer-service model applied to one of the most emotionally vulnerable experiences a person can have. Independent reproductive endocrinologists, who once had the flexibility to work with patients on payment plans or adjust protocols based on individual circumstances, are increasingly replaced by corporate clinical staff operating within profit-margin targets set by investors who have never held a patient's hand in a consultation room.

The absence of federal regulation compounds the problem. Unlike pharmaceutical drugs or medical devices, fertility treatments and the clinics that provide them face no meaningful federal price oversight, no standardized success-rate reporting requirements that are easily consumer-accessible, and no national mandate to ensure equitable access. The Federal Trade Commission has the theoretical authority to scrutinize anti-competitive consolidation in the healthcare sector, but enforcement in reproductive medicine has been essentially invisible.

Who Gets Left Behind — and It Is Not Random

The demographic shape of fertility treatment access in the United States is not incidental. It is structural. A 2023 study published in Fertility and Sterility found that Black and Hispanic women are significantly less likely to seek or receive fertility treatment than white women, even after controlling for income — a disparity researchers attributed to a combination of insurance gaps, geographic access, provider bias, and historical medical mistrust rooted in documented abuses. Low-income women of all backgrounds face the sharpest exclusion: a $20,000 price tag is simply a closed door when your household earns $55,000 a year.

Only nineteen states currently mandate some form of insurance coverage for fertility treatments, and even those mandates vary wildly in scope. Texas, Florida, Georgia, and most of the South offer no such protections. Federal employees gained limited fertility benefits in recent years, but Medicaid — the program that serves the poorest Americans — covers virtually nothing in this space. The result is a system in which a hedge fund manager in Connecticut can pursue IVF with minimal financial disruption, while a schoolteacher in Mississippi faces an impossible choice between parenthood and financial stability.

This is reproductive inequity, and it deserves to be named as such. The right to reproductive autonomy cannot be meaningfully exercised when access to reproductive medicine is rationed by wealth.

The Strongest Counterargument — and Why It Falls Short

Defenders of the status quo make two arguments worth engaging seriously. The first is that fertility treatment is elective — a preference, not a necessity — and that government or insurers should not be required to fund personal lifestyle choices. The second is that mandating coverage would drive up premiums for everyone, distributing costs unfairly across people who may never need or want fertility care.

Both arguments have surface plausibility and both ultimately fail. On the first: the World Health Organization's classification of infertility as a disease is not semantic — it reflects a clinical reality that fertility treatment addresses a medical condition, not a consumer preference. We do not typically apply the "elective" label to hip replacements or cardiac stents simply because the underlying condition does not threaten immediate survival. On the second: actuarial analyses of state mandates, including a widely cited study from the National Bureau of Economic Research, have found that fertility coverage mandates increase premiums by less than 1 percent — a modest cost spread across a large pool that delivers life-altering benefits to a significant minority.

What This Signals — and What Comes Next

The fertility industry's trajectory is a case study in what happens when essential human services are left entirely to market logic. Prices rise. Access stratifies. Consolidation accelerates. And the people most affected — working-class families, people of color, single parents, LGBTQ+ couples navigating a system not designed with them in mind — are precisely the people with the least political leverage to demand change.

Congress has shown occasional interest in expanding fertility access. The Access to Family Building Act, introduced in the Senate, would require coverage for IVF under employer-sponsored insurance plans, but the bill has repeatedly stalled. In the current political environment, with reproductive rights broadly under assault following the Supreme Court's Dobbs decision, the prospects for federal fertility legislation are uncertain at best. Some advocates worry, not without reason, that the political energy around reproductive rights is being narrowly channeled into abortion access — critically important, but incomplete without addressing the full spectrum of reproductive medicine.

States with progressive legislatures have an opportunity to act now: mandate coverage, cap out-of-pocket costs, require transparent success-rate reporting, and scrutinize clinic consolidation through existing antitrust tools. Federal action — whether through an expanded ACA mandate, Medicaid inclusion, or new standalone legislation — is the longer-term goal.

The capacity to build a family should not be a function of your net worth. Until America confronts the fertility industry's pricing structure, its consolidation crisis, and its regulatory vacuum with the seriousness they deserve, parenthood will remain, for too many, a privilege purchased rather than a right protected.